Petra M Nederlof

List of Publications by Year
in descending order

40 papers	3,080 citations	218677 26 h-index	289244 40 g-index
41 all docs	41 docs citations	41 times ranked	5104 citing authors

#	Article	IF	Citations
1	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. British Journal of Cancer, 2022, 126, 1401-1409.	6.4	11
2	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. Npj Breast Cancer, 2022, 8, 60.	5.2	11
3	Ovarian Cancerâ€“Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	7.0	9
4	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. Clinical Cancer Research, 2019, 25, 6598-6605.	7.0	17
5	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 673-680.	2.8	24
6	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clinical Cancer Research, 2018, 24, 6277-6287.	7.0	53
7	Estrogen receptor Î± wields treatment-specific enhancers between morphologically similar endometrial tumors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1316-E1325.	7.1	25
8	BRCA1-Mutated Estrogen Receptorâ€“Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency. Clinical Cancer Research, 2017, 23, 1236-1241.	7.0	19
9	Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study. BMC Cancer, 2016, 16, 811.	2.6	13
10	Proper genomic profiling of (BRCA1â€mutated) basalâ€like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. Molecular Oncology, 2015, 9, 877-888.	4.6	16
11	Robust BRCA1â€like classification of copy number profiles of samples repeated across different datasets and platforms. Molecular Oncology, 2015, 9, 1274-1286.	4.6	29
12	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	5.0	86
13	Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy. Cancer Immunology Research, 2014, 2, 538-546.	3.4	29
14	Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Research and Treatment, 2013, 139, 317-327.	2.5	20
15	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. PLoS ONE, 2013, 8, e55734.	2.5	29
16	Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Research and Treatment, 2012, 132, 379-389.	2.5	47
17	BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature, 2011, 477, 179-184.	27.8	403
18	Genomic signature of BRCA1 deficiency in sporadic basalâ€like breast tumors. Genes Chromosomes and Cancer, 2011, 50, 71-81.	2.8	53

#	Article	IF	Citations
19	Oncogenesis and classification of mixedâ€type liposarcoma: A radiological, histopathological and molecular biological analysis. International Journal of Cancer, 2011, 128, 778-786.	5.1	11
20	Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR. PLoS ONE, 2011, 6, e17791.	2.5	166
21	Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. Annals of Surgical Oncology, 2010, 17, 686-693.	1.5	28
22	Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes and Cancer, 2010, 49, 699-710.	2.8	17
23	Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients. Clinical Cancer Research, 2010, 16, 651-663.	7.0	61
24	High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer. Cancer Research, 2009, 69, 3625-3633.	0.9	142
25	Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes and Cancer, 2009, 48, 544-551.	2.8	25
26	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Research and Treatment, 2009, 116, 479-489.	2.5	124
27	Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. Modern Pathology, 2009, 22, 223-231.	5.5	74
28	Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Research and Treatment, 2008, 112, 99-108.	2.5	36
29	Genomeâ€wide linkage scan in Dutch hereditary nonâ€BRCA1/2 breast cancer families identifies 9q21â€22 as a putative breast cancer susceptibility locus. Genes Chromosomes and Cancer, 2008, 47, 947-956.	2.8	16
30	Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. European Journal of Human Genetics, 2008, 16, 820-832.	2.8	42
31	Analysis of PALB2/FANCN-associated breast cancer families. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6788-6793.	7.1	192
32	Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?. Clinical Cancer Research, 2005, 11, 6608-6614.	7.0	87
33	Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Research, 2005, 65, 822-7.	0.9	97
34	Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood, 2003, 102, 324-327.	1.4	40
35	Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Research, 2003, 63, 1449-53.	0.9	233
36	Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Research, 2002, 62, 7110-7.	0.9	123

#	Article	IF	Citations
37	Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nature Genetics, 2000, 26, 291-299.	21.4	335
38	Proteasome: from structure to function. Current Opinion in Biotechnology, 1996, 7, 376-385.	6.6	26
39	In situhybridisation with fluoresceinated DNA. Nucleic Acids Research, 1991, 19, 3237-3241.	14.5	196
40	Detection of chromosome aberrations in interphase tumor nuclei by nonradioactive in situ hybridization. Cancer Genetics and Cytogenetics, 1989, 42, 87-98.	1.0	114